An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia R/R-AML with an Isocitrate Dehydrogenase-2 IDH2 Mutation

Brief Summary

Type:
Leukemias

Study Type:
Treatment

Phase:
Feasibility/Pilot

ClinicalTrials.gov Identifier:
NCT04203316

Study #:
CMH - ADVL18P1

Start Date:
May 25, 2020

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04203316

View Complete Trial Details & Eligibility at ClinicalTrials.gov